165 related articles for article (PubMed ID: 31556584)
21. Core-shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells.
Surnar B; Sharma K; Jayakannan M
Nanoscale; 2015 Nov; 7(42):17964-79. PubMed ID: 26465291
[TBL] [Abstract][Full Text] [Related]
22. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
23. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
[TBL] [Abstract][Full Text] [Related]
24. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
25. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
26. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
27. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable and pH-Responsive Acetalated Dextran (Ac-Dex) Nanoparticles for NIR Imaging and Controlled Delivery of a Platinum-Based Prodrug into Cancer Cells.
Braga CB; Perli G; Becher TB; Ornelas C
Mol Pharm; 2019 May; 16(5):2083-2094. PubMed ID: 30901218
[TBL] [Abstract][Full Text] [Related]
29. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
30. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer.
Li Q; Qin T; Bi Z; Hong H; Ding L; Chen J; Wu W; Lin X; Fu W; Zheng F; Yao Y; Luo ML; Saw PE; Wulf GM; Xu X; Song E; Yao H; Hu H
Nat Commun; 2020 Mar; 11(1):1456. PubMed ID: 32193458
[TBL] [Abstract][Full Text] [Related]
31. Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer.
Paul M; Ghosh B; Biswas S
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128281. PubMed ID: 37992920
[TBL] [Abstract][Full Text] [Related]
32. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles.
Cao ZT; Chen ZY; Sun CY; Li HJ; Wang HX; Cheng QQ; Zuo ZQ; Wang JL; Liu YZ; Wang YC; Wang J
Biomaterials; 2016 Jul; 94():9-19. PubMed ID: 27088406
[TBL] [Abstract][Full Text] [Related]
33. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
35. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
36. Photo-responsive prodrug nanoparticles for efficient cytoplasmic delivery and synergistic photodynamic-chemotherapy of metastatic triple-negative breast cancer.
Jiao J; Lu H; Wang S
Acta Biomater; 2021 May; 126():421-432. PubMed ID: 33774201
[TBL] [Abstract][Full Text] [Related]
37. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
38. Nano-delivery of
Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
[TBL] [Abstract][Full Text] [Related]
39. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
[TBL] [Abstract][Full Text] [Related]
40. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
